Evidence indicates that patients with COVID-19 exhibit a robust neuroinflammatory response, including elevated levels of IFN-α, IFN-γ, IL-6, interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-18 (IL-18), CXCL10, and nucleotide-binding oligomerization domain-containing protein 2 (NOD2), compared to healthy individuals [57,58,59]. This evidence concerns the gene IL18 and COVID-19.